Hyperglycemia affects Matrix Metalloproteinase Secretion in Human Umbilical Vein Endothelial Cells in vitro by Lillo, Astrid
  
Hyperglycemia affects Matrix 
Metalloproteinase-2 Secretion in 
Human Umbilical Vein Endothelial 
Cells in vitro 
 
Master thesis by  
 
Astrid Lillo 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
        Supervisors: Svein Olav Kolset and Astri Jeanette Meen 
 
 
Department of Nutrition 
Institute of Basic Medical Sciences 
Faculty of Medicine 
University of Oslo  
 
II 
 
 
III 
 
Abstract 
Goal: The aim of the current thesis was to study the effect of hyperglycemia (HG) on MMP 
secretion from human primary endothelial cells.  
Background: Diabetes Mellitus is characterized by abnormal high levels of glucose in the 
blood. Endothelial dysfunction is a serious complication of sustained hyperglycemia. Diabetic 
complications are main reasons for mortality in diabetes. The matrix metalloproteinases 
(MMPs) and their corresponding inhibitors are the main regulators of the turnover of 
extracellular matrix (ECM) components, and have been suggested to play an important role in 
vascular remodelling taking place in diabetes. MMP secretion from endothelial cells may 
become altered in HG conditions and result in dysregulation of ECM turnover, which may 
affect vascular functions with relevance to diabetes. HG conditions may also affect 
intracellular signalling through pathways sensing changes in cellular glucose, such as the 
hexosamine pathway  
Methods: Primary human umbilical vein endothelial cells (HUVEC) were cultured in vitro as 
a model system of the human endothelium. HUVEC were exposed to HG (25 mM) to imitate 
the diabetic hyperglycemic state and the effect on secretion of MMP-2 and MMP-9 was 
quantified. MMP secretion was analyzed by gelatine zymography. HUVEC were cultured on 
traditional plastic wells and on semipermeable filter inserts. The effect of blocking the 
hexosamine pathway using the inhibitor DON, on MMP secretion was also investigated. The 
O-GlcNAcylated proteins were analyzed by Western blotting. Bands obtained after gelatine 
zymography were measured using the programme Quantity-One (Bio-Rad). 
Results: Results obtained suggest that there is a weak trend of reduction in MMP-2 secretion 
in HUVEC grown on plastic. However, variable results were discovered in HUVEC grown on 
filters. The filter experiments showed that MMP-2 was mostly secreted to the apical side of 
polarized HUVEC. Finally, exposing HUVEC to DON caused a decrease in MMP-2 secretion 
both on plastic and on filter. MMP-9 secretion was not detected in any of the current 
experiments.  
Conclusions: The present work showed that HG influences MMP secretion, indicating a 
reduction in MMP-2 secretion in HUVEC grown on plastic. However, results were not 
definite and further investigations are needed to study the effects of hyperglycemia on MMP-
2 secretion in cultures of primary human endothelial cells and to further investigate the 
potential role of MMPs as a therapeutic target in diabetes. 
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1 Introduction 
1.1 Diabetes 
Diabetes Mellitus (DM) is a group of chronic diseases, which arise when the pancreas is 
unable to produce enough insulin or when the body does not effectively use the insulin it 
produces. The lack of insulin production or the insensitivity to the hormone, ultimately leads 
to hyperglycemia, which can be described as an excess of glucose in the blood (WHO, 2011; 
Thomas & Bishop, 2007). There are as many as 366 million people worldwide who have 
diabetes and this number is projected to rise to 522 million by 2030 (International Diabetes 
Federation, 2011). In Norway, approximately 375 000 people have diabetes, in which 350 000 
of these are afflicted with type 2 DM (Diabetesforbundet, 2008).  
 
1.2 Types of diabetes 
There are several forms of diabetes. Most cases can be categorized into type 1 or type 2 DM. 
Type 1 DM is characterized by a partial or total failure of insulin production as a result of 
destruction of the pancreatic beta cells. Although the disease is considered to arise from an 
autoimmune response, the initializing event for beta cell destruction is currently not known in 
detail. Type 2 DM is the most prevalent type of diabetes, accounting for at least 75% of 
diabetes cases (Thomas & Bishop, 2007). The decline in physical activity and rise in obesity 
rates in the western world are two major reasons behind the epidemic like increase in type 2 
DM (Wild et al., 2004). The disease occurs either due to a lack of insulin production, or 
insensitivity to insulin, or both. In addition to being strongly linked to obesity, with 80% of 
patients with type 2 DM being overweight or obese, type 2 DM is also linked to genetic 
predispositions (Thomas & Bishop, 2007). 
Gestational diabetes mellitus (GDM) is another form of diabetes that occurs in approximately 
1-14% of all pregnancies, depending on the population studied. GDB arises due to the 
mother’s inability to produce enough insulin to meet the extra demands of pregnancy. The 
risk of developing GDB increases with age (> 25 y), and is more prevalent in women with a 
family history of diabetes, women from an ethnic or racial group with high prevalence of 
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diabetes, such as Asian, African or Hispanic, or in women who are overweight or obese 
(American Diabetes Association, 2003). Even though the occurrence of GDB is generally 
temporarily, it increases the risk of developing type 2 DM in later life (Thomas & Bishop, 
2007). 
 
1.2.1 Diagnosis 
Diagnosis of diabetes is characterized by a random venous plasma glucose concentration over 
11.1 mM or a fasting venous plasma glucose concentration greater than 7 mM. An oral 
glucose tolerance test (OGTT) 2 h after consuming 75 g of anhydrous glucose is used to 
confirm diagnosis of diabetes (Thomas & Bishop, 2007). 
 
1.3 Diabetic complications 
Diabetic complications are major causes of morbidity and mortality in diabetic patients 
(Kitada et al., 2010). Complications can generally be classified as macrovascular and 
microvascular. Macrovascular complications are diseases of the large blood vessels, and 
encompass coronary artery disease, peripheral arterial disease and stroke. Atherosclerosis can 
lead to a narrowing of arterial walls in the body and is a central mechanism in the 
development of macrovascular diseases. Microvascular complications are diseases of the 
smaller blood vessels and include diabetic nephropathy, neuropathy and retinopathy. Lifestyle 
changes and medical treatment are important for lessening hyperglycemia-induced damages 
in the vascular tissues and in the prevention of micro- and macrovascular complications 
(Fowler et al., 2008; Thomas & Bishop, 2007).  
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1.3.1 Diabetic Nephropathy 
Diabetic nephropathy is the main cause of renal failure in the United States. It is defined by 
proteinuria > 500 mg/24 h in the presence of diabetes, but starts with lower levels of 
proteinuria also referred to as “microalbuminuria”. Microalbuminuria refers to an abnormal 
increase in albumin excretion rate within 30-299 mg in 24 h. Daily albumin excretion rate is 
in the range of 5-10 mg under normal conditions (Toto, 2004). Diabetic nephropathy is 
present in 20-30% of patients with type 1 and type 2 diabetes, and the prevalence is as much 
as 40-50% in type I diabetes patients who have had the disease for more than 20 years 
(Thrailkill et al., 2009). There are a number of risk factors associated with the development of 
nephropathy including age at diagnosis, race, hypertension, poor glycemic control, genetic 
predisposition to kidney disease, and dietary composition.  However, the specific pathogenic 
process implicated in the initiation and progression of renal disease is not completely 
understood. A five-stage process of the development of diabetic nephropathy has been 
suggested (Thrailkill et al., 2009): Renal disease initiates with glomerular hyperfiltration and 
hypertrophy of the kidneys (stage 1). The glomerular basement thickens (stage 2), leading to 
microalbuminuria and a decrease in glomerular filtration rate (stage 3), developing to 
proteinuria and severe hypertension (stage 4), and finally, developing into end stage renal 
disease (stage 5). The expansion of the kidney mesangium is a result of ECM over-
accumulation and is a significant characteristic of renal disease.  
During normal matrix remodelling, matrix metalloproteinases (MMPs) produced by the 
mesangial cells are responsible for approximately 70% of the ECM turnover in the kidney. 
Thus, an association between intrarenal dysregulation of MMP activity and the progression of 
diabetic nephropathy has been suggested as many studies have reported a link between MMP 
dysregulation and diabetic nephropathy (Thrailkill et al., 2009; Catania et al., 2006). Aberrant 
MMP activity has also been linked to several other complications of diabetes, such as diabetic 
retinopathy (Thrailkill et al., 1999; Thrailkill et al., 2009; Tsilibary, 2003; Lokesh & 
Veeranjaneyulu, 2003), peripheral arterial disease and acute coronary syndrome (Thrailkill et 
al., 2009). Changes in MMP synthesis, secretion and activities may therefore have vital roles 
in diabetes pathogenesis. This family of proteases are further described in chapter 1.9. 
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1.4 The Vascular Endothelium 
The vascular endothelium consists of a single sheet of endothelial cells located on the internal 
lumen of all blood vessels, lining the entire vascular system from the heart to the smallest 
capillary (Figure 1.4) (Singh et al., 2010). The endothelium weighs approximately 1 kg, 
making it one of the largest “organs” in the human body.  
The endothelium functions as a semipermeable barrier between the blood stream and the 
vascular smooth muscle tissue. This barrier allows movement of small solutes in preference to 
large molecules. The endothelium is implicated in numerous homeostatic processes. The 
physiological functions of the endothelium include regulation of blood coagulation, 
vasoconstriction and vasodilation, management of growth and differentiation of vascular 
smooth muscle cells (VSMC), regulation of the subendothelial matrix and the modulation of 
inflammatory activity in the vessel wall. Changes in ability of the endothelium to regulate 
some or all of its functions results in endothelial dysfunction (Sing et al., 2010). The 
endothelium produces a range of substances in order to perform its functions, such as nitric 
oxide (NO), prostanoids, endothelin-1 (ET-1), Ang-II (angiotensin-II), t-PA (tissue-type-
plasminogen activator), von Willebrand factor (vWF), and cytokines (Schalkwijk & 
Stehouwer, 2005). NO is one of the major vasodilatory agents synthesized by the 
endothelium, and it also inhibits growth and inflammation. Other inflammatory substances 
include intracellular adhesion molecule-1, E-selectin and NF-κB (Endemann & Schiffrin, 
2004). 
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Figure 1.4. The endothelium consists of a monolayer of 
endothelial cells. The endothelium is involved in 
numerous homeostatic processes, including vasotone 
regulation (vasoconstriction and vasodilation), regulation 
of growth and differentiation of vascular smooth muscle 
cells (VSMC), and regulation of inflammatory activity  
(Figure has been adapted from Chelation Health Products, 
2008.) 
 
 1.4.1 Endothelial dysfunction 
The endothelium is versatile and multifunctional, and is distributed in all organ systems. 
Thus, its dysfunction is not restricted to any specific organ or to the pathogenesis of 
atherosclerosis (Malyszko, 2010; Feletou & Vanhoutte, 2006). Endothelial dysfunction can be 
described as the inability of the endothelial cells to control some or all of their functions and 
can be characterized by reduced vasodilation, a proinflammatory condition, and a prothrombic 
state. Endothelial dysfunction is commonly associated with a decline in NO bioavailability; 
due to reduced NO production by the endothelium or an inactivation of NO caused by an 
increase in reactive oxygen species (ROS) production (Endemann & Schiffrin, 2004). 
Endothelial dysfunction is a critical complication of sustained hyperglycemia, and is 
commonly seen in patients with cardiovascular disease, diabetes and hypercholesterolemia 
(Endemann & Schiffrin, 2004). The pathogenesis of endothelial dysfunction in type 1 and 2 
DM has not been established, and the underlying processes resulting in endothelial 
dysfunction may be different in the two pathologies. However, several common risk factors 
appear to play an important part in the progression of endothelial dysfunction in both 
conditions, including hypertension, poor glycemic control, microalbuminuria, dyslipidaemia, 
poor antioxidant status, and smoking (Singh et al., 2010). In diabetes, various factors are 
considered to give rise to endothelial dysfunction including the level of hyperglycemia, 
duration of diabetes, accumulation of advanced glycation end products (AGEs), and the 
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presence of complications such as nephropathy and albuminuria (Feletou & Vanhoutte, 2006). 
Vascular remodelling is considered to play a crucial role in pathogenesis of arterial and 
venous disease. Changes to the cellular and ECM components result in structural and 
functional modifications of the vessel wall. These modifications may lead to atherosclerosis, 
contributing to plaque initiation and progression, or weakening of the vascular wall causing 
vessel dilation (Lim et al., 2010). Changes in basement membrane synthesis may give rise to 
altered matrix composition, which can result in arterial stiffening, increased microvascular 
permeability and vascular tone as seen in diabetes and atherosclerosis (Stehouwer, 2004). The 
retention hypothesis postulates that proteoglycans are involved in the retention of atherogenic 
lipoproteins, being an early event in atherogenesis. Retained lipoproteins become modified 
(oxidized) and can cause lesions and induce increased synthesis of proteoglycans, which may 
lead to further retention of lipoproteins and aggregation (Skålen et al., 2002). One problem 
with diabetes treatment is that endothelial function may not be improved or restored (Feletou 
& Vanhoutte, 2006). 
 
The endothelial glycocalyx 
The glycocalyx can be regarded as a “gatekeeper” and is located between the blood stream 
and the endothelial layer (Figure 1.4.1). The glycocalyx consists of proteoglycans and 
glycoproteins and functions as a protective barrier, regulating blood clotting, blood flow and 
inflammation (Reitsma et al., 2007; Noble et al., 2008). Damage to the glycocalyx is 
considered to arise from enzymatic and pressure-induced shedding. The MMPs are known to 
take part in the shedding of syndecans (transmembrane domain proteins) from the glycocalyx 
and are referred to as sheddases (Lipowsky, 2011; Manon-Jensen et al., 2010). In vitro, it has 
been shown that the ectodomain of syndecans is continuously shed from cells. This process is 
accelerated in wound healing and various diseases (Manon-Jensen et al., 2010). In vivo, 
studies have shown that shedding of the endothelial glycocalyx occurs under inflammation 
and hyperglycemia.  Dysfunction of the glycocalyx has been proposed to contribute to 
endothelial dysfunction in hyperglycemic conditions (Reitsma et al., 2007). MMPs are 
capable of modifying the endothelial glycocalyx and facilitate shedding in disease states 
(Lipowsky, 2011).  
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Figure 1.4.1. The image shows the 
glycocalyx layer above the endothelial 
cell (Figure taken from Rutledge et al., 
2010). 
 
1.4.2 Endothelial dysfunction and inflammation 
Over time diabetes can lead to a condition of low-grade inflammation in the circulatory 
system. Causes for inflammation include hyperglycemia, generated advanced glycation 
endproducts (AGEs) and increased levels of tumour necrosis factor-α (TNF-α). Endothelial 
dysfunction contributes to vascular inflammation by the generation of vasocontrictor agents, 
release of adhesion molecules and growth factors (Savoia & Schiffrin, 2007; Stehouwer, 
2004). Inflammation is a defensive biological response to a pathological stimulus or tissue 
injury (Roy et al., 2009). It is hypothesized that inflammatory molecules have a key role in 
the development of diabetes complications in particular diabetic nephropathy, although the 
mechanisms behind this is not clear (Goldberg, 2009). Proteinuria is an important stage in the 
development of diabetic nephropathy and is closely correlated with inflammation (Navarro-
Gonzalez et al., 2011). 
An early event of inflammation is the secretion of chemokines from affected tissues including 
monocyte chemoattractant protein (MCP-1) and macrophage migration inhibition factor 
(MIF) (Goldberg, 2009). These factors and others induce the secretion of a range of adhesion 
molecules from the endothelium, including leukocyte adhesion molecules (LAM), 
intracellular adhesion molecules (ICAM), and vascular cell adhesion molecules (VCAM). The 
adhesion molecules, which are located on the cell surface, and regulate cell-cell and cell-
8 
 
matrix interactions, have a regulatory role in inflammation and attract cells implicated in the 
inflammatory reaction including monocytes, granulocytes and other immune cells (Hadi & 
Suwaidi, 2007; Aldahi & Hamdy, 2003; Goldberg, 2009).  
Adipose tissue is a major contributor to inflammation in overweight patients, which is 
important as obesity is strongly linked to type 2 diabetes (Goldberg, 2009; Thomas & Bishop, 
2007). TNF-α is secreted from adipocytes. Thus, increased adipose tissue can result in higher 
levels of TNF-α in overweight subjects, which can contribute to inflammation, e.g. through 
activation of endothelial cell expression of leukocyte adhesion molecules (Aldahi & Hamdy, 
2003).
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1.5 Hyperglycemia activates the flux through four 
major pathways 
Endothelial dysfunction is a multifaceted disorder and occurs in many different disease 
processes. Despite this, oxidative stress can be identified as a fundamental common factor, 
giving rise to endothelial dysfunction (Feletou & Vanhoutte, 2006). Chronic hyperglycemia 
causes increased oxidative stress and an impaired antioxidant response in endothelial cells of 
both small and larger vessels (Singh et al., 2011). In diabetes, every cell in the body is 
exposed to unusual high concentrations of glucose. While some cells are able to regulate 
glucose uptake according to the levels of glucose concentration in the cellular environment, 
other cells are not able to control the flux of glucose. Vascular endothelial cells are major 
targets for hyperglycemic damage, as they do not appear to alter the transport of glucose when 
glucose concentration is increased, ultimately leading to intracellular hyperglycemia (Giacco 
& Brownlee, 2010). This strongly indicates that the cause for the complications include 
mechanisms taking place inside the cell, rather than outside. Four pathways have been 
recognized as being important in the progression of diabetic complications and they all share 
one single hyperglycema-induced process, which is the overproduction of superoxides by the 
mitochondrial electron transport chain (Figure 1.5) (Brownlee, 2005). 
Hyperglycemia causes the activation of four major pathways:  
1. An increase in polyol pathway flux 
2. Activation of Protein kinase C (PKC) isoforms 
3. Increased formation of AGE products  
4. Excess shunting through the hexosamine pathway.  
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Figure 1.5. Hyperglycemia increases the flux through four major pathways. The four pathways 
are the polyol pathway, hexosamine pathway, PKC, and AGE pathway (Figure is taken from 
Brownlee, 2005). 
 
1.5.1 Increased flux through the polyol pathway 
In the polyol pathway, intracellular glucose is converted to sorbitol in a rate-limiting step 
catalyzed by the enzyme aldose reductase (AR), in a NADPH dependent reaction. Next, 
sorbitol is oxidized to fructose by sorbitol dehydrogenase (SDH). Under normal glucose 
conditions, only a small fraction of glucose is metabolized through this pathway. In diabetic 
states however, the increase in intracellular glucose levels may lead to an increased flux of 
glucose trough AR. NADPH which is used in this reaction, is also a vital cofactor for 
regenerating an important intracellular antioxidant, reduced glutathione (GSH). If the amount 
of reduced GSH is decreased, the polyol pathway increases susceptibility to a lower 
production of NO and leads to an increase in oxidative stress (Brownlee, 2005). 
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1.5.2 Increased protein kinase C activation 
The PKC family is made up of at least eleven isoforms, which are all activated by the lipid 
messenger diacylglycerol (DAG). Intracellular hyperglycemia increases synthesis of DAG. 
Moreover, several PKC isoforms are activated by other mechanisms, such as ROS and free 
fatty acids (FFA). Increased protein kinase C activation has been linked to a variety of 
changes in gene expression, such as a decrease in endothelial nitric oxide synthase (eNOS) 
that produces the vasodilator NO, an increase in the expression of endothelin-1, tumor growth 
factor-β (TGF- β) and the plasminogen activator inhibitor (PAI-1). This may then lead to 
changes in blood flow, basement membrane thickening, ECM expansion, an increase in 
vascular permeability, and abnormal angiogenesis (Giacco & Brownlee, 2010). 
 
1.5.3 Increased AGE formation  
AGE products are made when glucose reacts with proteins in a non-enzymatic way. A series 
of chemical rearrangements results in AGEs. In diabetes, AGEs are found to accumulate in 
the ECM, both in the vasculature and in organs such as the kidneys. There are three general 
ways in which intracellular production of AGE precursors can harm cells.  
1. Intracellular proteins modified by AGEs have changed functions. 
2. ECM components can be modified by AGEs, which changes the composition and 
functions of ECM, signalling between the matrix and the cell, which may contribute to 
e.g. endothelial dysfunction.  
3. Plasma proteins such as albumin can be modified by AGE precursors and bind to AGE 
receptors (RAGE) on cells such as macrophages, vascular endothelial cells and 
vascular smooth muscle cells. The binding of plasma proteins to RAGE instigates the 
generation of ROS, which in turn initiates the transcription factor NF-ĸB, resulting in 
many pathological changes in gene expression (Brownlee, 2001). 
Studies have shown that serum and tissue AGEs levels are significantly increased in type 1 
and type 2 diabetes patients compared to non-diabetics (Berg et al., 1997 & Berg et al., 1998). 
Moreover, it has been found that diabetic patients with end-stage renal disease have 
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approximately twice AGEs in tissue in comparison to diabetic patients with no renal disease 
(Makita et al., 1991). Excess AGEs in kidney is suggested to be responsible for alteration in 
renal structure and loss of renal function. AGE formation on different types of matrix proteins 
impairs their breakdown by MMPs, contributing to thickening of the basement membrane and 
mesangial expansion, which are characteristics of diabetic nephropathy. AGE triggers TGF-β 
expression, which in turn induces the generation of the important ECM proteins collagen, 
laminin and fibronectin. AGE-induced TGF-β expression has also been shown to give rise to 
tubulointerstitial fibrosis in diabetic nephropathy (Yamagashi & Matsui, 2010). 
 
1.6 Increased flux through the hexosamine pathway 
There is a strong correlation between type 2 DM and nutrient availability. However, the 
mechanism by which nutrient excess leads to type 2 DM is not completely understood. Many 
metabolic and signalling pathways have been hypothesized to play a role in the development 
of diabetes. One of these is the hexosamine pathway (Wells & Hart, 2003), which has been 
studied in this thesis in regard to the secretion of MMPs. Excess shunting through the 
hexosamine pathway caused by hyperglycemia may give rise to changes in both gene 
expression and protein function, and can play a crucial role in the progression of diabetic 
complications (Wells & Hart, 2003, Brownlee, 2005, Hart et al., 2011).  
Glucose can enter cells via glucose transporters (GLUTs) and is metabolized to fructose-6-
phosphate (F-6-P) by the enzyme hexokinase and continues into glycolysis (Figure 1.6). In a 
normal glucose state, only a small amount of glucose (2-5%) is metabolized through the 
hexosamine pathway (Laczy et al., 2008; Schleicher & Weigert, 2000). In the presence of 
chronic hyperglycemia, the flux through this pathway increases. F-6-P is metabolized into 
glucosamine-6-phosphate (G-6-P) by the rate-limiting enzyme glutamine: fructose-6-
phosphate amidotransferase (GFAT). In this process glutamine is amine donor and the 
activity of GFAT can be blocked using the glutamine analogues 6-diazo-5-oxo-norleucine 
(DON) or azaserine (AZA). Two different isoforms, GFAT1 and GFAT2, have been 
identified in humans, sharing 75% identity (Nakaishi et al., 2009). A northern blot analysis 
revealed different expression of the two variants in different tissues. A higher expression of 
GFAT1 was found in placenta, testis and pancreas, whereas GFAT2 expression was more 
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abundantly found in heart and central nervous tissue. GFAT activity is strictly regulated by 
cAMP-dependent phosphorylation. However, phosphorylation of GFAT1 reduces its activity 
in vitro, in contrast to increasing the activity of GFAT2. Different expression and activity of 
the two isoforms suggest that the enzymes have separate roles in diabetic pathophysiology 
(Laczy et al., 2008). One report studied the expression of both enzymes (using an antibody 
recognizing the C-terminus of GFAT) in various tissues in healthy human subjects. The 
immunohistochemical study revealed a high expression of GFAT in adipocytes, skeletal 
muscle and VSMC. Surprisingly, glomerular cells remained unstained. However, analysis of 
renal sections from subjects with diabetic nephropathy showed a significant staining of 
glomerular cells, suggesting that the enzyme is induced in diabetes (Schleicher & Weigert, 
2000). Increased activity of human GFAT has been linked to insulin resistance in 
experimental in vitro models (Nakaishi et al., 2009).  
The major end product in the hexosamine pathway is UDP-N-acetylglucosamine (UDP-
GlcNAc), which is a substrate for the subsequent O-linked GlcNAc modifications of target 
proteins at serine and threonine residues. The quantity of UDP-GlcNAc in the cell indicates 
the flux of glucose through this pathway. UDP-GlcNAc can be considered as a metabolic 
sensor capable of modifying proteins according to changes in intracellular glucose 
concentration and availability (Issad et al., 2010). UDP-GlcNAc is an allosteric inhibitor of 
GFAT and regulates the flux of glucose into the hexosamine pathway. From this pathway 
UDP-GlcNAc can either continue into the endoplasmic reticulum (ER) or Golgi where it used 
as an essential building block to synthesize glycolipids, proteoglycans or glycoproteins, or it 
can go through the “signalling” pathway, where it used to modify nuclear and cytosolic 
proteins by O-GlcNAcylation (Figure 1.7), further described on the following pages (Buse, 
2006).  
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Figure 1.6. Overview of the hexosamine pathway. UDP-GlcNAc can be regarded as a nutrient 
sensor capable of modifying proteins depending on glucose availability. The nucleotide sugar UDP-
GlcNAc can either be used as a precursor for synthesis of proteoglycans, glycolipids and 
glycoproteins, or it can be used in a translational modification of proteins, described as O-
GlcNAcylation: a process in which UDP-GlcNAc is added on to serine and threonine residues in an O-
linkage by the enzyme O-GlcNAc-transferase (OGT) and removed by O-GlcNAcase (Figure is 
adapted from Buse, 2006). Text in green displays the action of enzymes involved in the pathway, 
while the red lines indicate where the inhibitors act. 6-diazo-oxo-norleucine (DON) and azaserine 
(AZA) prevent the action of the enzyme GFAT, while PUGNAC (O-(2-Acetamido-2-deoxy-D-
glucopyranosylidene) amino N-phenyl carbamate) inhibits the action of O-GlcNAcase. 
 
1.7 O-GlcNAcylation 
O-linked-N-acetylglucosaminylation (O-GlcNAcylation) was initially discovered by G.W. 
Hart in 1984 (Torres & Hart, 1984) and is described as the addition and removal of N-
acetylglucosamine (GlcNAc) on the hydroxyl group of serine or threonine residues on 
different proteins (Figure 1.7). O-GlcNAc modification is a highly dynamic, post-
translational modification, similar to phosphorylation that appears to be an essential 
regulatory mechanism in signalling pathways (Issad et al., 2010). However, unlike 
phosphorylation only two key enzymes regulate the addition and removal of O-GlcNAc on 
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proteins. O-GlcNAc-transferase (OGT) catalyses the addition of O-GlcNAc to proteins, while 
O-GlcNAcase catalyses the removal of the sugar molecule (Fülöp et al., 2007). O-
GlcNAcylation competes with phosphorylation for the same serine or threonine residues, 
which can then affect the phosphorylation status of a protein (Issad et al., 2010).  
 
Figure 1.7. The addition and removal of O-GlcNAc from serine and threonine residues is catalyzed by 
the two enzymes: OGT and O-GlcNAcase (figure is from Hart et al., 2007). 
 
1.7.1 The hexosamine pathway and insulin resistance 
Several investigations in cell culture and in rodents in vivo, have found that an increased flux 
through the hexosamine pathway can result in insulin resistance (Buse, 2006). Marshall et al. 
(1991) were the first to describe the role of the hexosamine pathway in the development of 
insulin resistance. They demonstrated that insulin insensitivity was induced in rat adipocytes 
cultured in medium containing a high-glucose concentration, insulin and glucosamine (Issad 
et al., 2010). The effect of these agents was prevented when blocking the enzyme GFAT 
using the inhibitors AZA or DON (Zachara & Hart, 2006). In addition to hyperglycemia, 
insulin and glucosamine treatment, the elevation of free fatty acids and over-expression of 
GFAT have all shown to increase the flux through the hexosamine pathway and lead to 
different degrees of insulin resistance (Wells & Hart, 2003). Considering that O-GlcNAc 
modification is dependent on flux through the hexosamine pathway, it has been suggested to 
be a potential mediator of insulin resistance (Wells et al., 2003). The dysregulation of O-
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GlcNAc modification is associated with a number of human diseases, particularly diabetes 
(Hart et al., 2007).  
Investigations conducted by Marshall et al. (1991) demonstrated that inhibition of GFAT 
blocks hyperglycemia-induced increases in the transcription of TGF-α, TGF-β1 and 
plasminogen activator inhibitor-1 (PAI-1) (Nerlich et al., 1998). The mechanisms by which 
increased flux through the hexosamine pathway, lead to hyperglycemia-induced increases in 
gene transcription has not yet been determined. However, studies have shown that 
hyperglycemia give rise to a 4-fold increase in O-GlcNAcylation of the transcription factor 
Specificity Protein 1 (Sp1), inducing activity of TGF-β1 and PAI-1 in arterial endothelial cells 
(Brownlee, 2001; Kitada et al., 2010; Hart et al., 2007). O-GlcNAc is postulated to play a 
central role in modulating insulin signalling (Figure 1.8) and in the development of glucose 
toxicity. Hyperglycemia leads to the conversion of glucose to glucosamine, which in turn 
results in an increase of the “nutrient sensor” UDP-GlcNAc, ultimately causing a rise in O-
GlcNAcylation. The increase in O-GlcNAcylation on insulin receptor substrate (IRS) appears 
to reduce the interaction with phosphatidylinositol-3-OH kinase (PI3K), blocking insulin 
signalling at an early point in time (Hart et al., 2007). Moreover, many studies have shown 
that the translocation of insulin-dependent GLUT4 to the membrane is inhibited when the flux 
through the hexosamine pathway is increased. This has been related to a defect in AKT (also 
known as protein kinase B) phosphorylation and activation, as a result of hyperglycemia or 
glucosamine treatment. Thus, it appears that increased movement through this pathway blocks 
signal transduction at or upstream of AKT (Wells et al., 2003).  
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Figure 1.8. Overview of insulin 
signalling pathway. Binding of insulin 
to the insulin receptor (IR) leads to a 
conformational change in the IR, 
resulting in a signalling cascade inside 
the cell. Receptor activation initiates 
phosphorylation of IRS (insulin receptor 
substrate), triggers the activation of 
phosphoinositide 3-Kinas (PI3K) and 
AKT (PKB), causing the translocation 
of GLUT4 to the cell membrane, and 
thereby allowing glucose to be taken up 
into the cell (Rexford et al., 2010) 
(Figure is adapted from Lebeche, 2008).  
 
1.8 Extracellular Matrix and diabetes 
The extracellular matrix (ECM) is a dynamic interactive milieu that critically influences cell 
functions. The ECM consists of a network of collagens, elastins, structural glycoproteins, 
proteoglycans and hyaluronan. This network maintains a mechanical support for cells and 
allows complex interactions to take place between cells, or between cells and the ECM (Ban 
& Twigg, 2008). There is a continuous synthesis and degradation of the ECM components. 
The turnover of the ECM is vital for normal growth and development, in addition to cell 
functions. A disruption of this balance may result in a build-up of ECM molecules. The 
MMPs and their corresponding tissue inhibitors of metalloproteinases (TIMPS) are main 
regulators of ECM turnover and homeostasis. An imbalance between MMP levels and their 
inhibitors may shift the equilibrium of the matrix turnover towards matrix accumulation or 
increased degradation. Changes in vascular structure contribute to the pathogenesis of 
vascular complications of diabetes (Lenz et al., 2000). Fibrosis is described by a build-up of 
ECM components and by vascular remodelling. The accumulation of ECM and the thickening 
of the basement membrane are commonly seen in the major organs affected in diabetes (Ban 
& Twigg 2008). Increased matrix accumulation in the endothelium also contributes to the 
accumulation of lipoprotein, through retention, described previously. 
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1.9 Matrix metalloproteinases  
Structure and function of matrix metalloproteinases  
MMPs belong to the metzinicin superfamily of metalloproteinases. The enzyme family 
comprise of 23 zinc and calcium dependent enzymes, which have been found in humans 
(Figure 1.9) (Offersen et al., 2010; Hadler- Olsen et al., 2011) that share common functional 
domains. MMPs can be separated into 6 groups based on substrate specificity (Kadoglou et 
al., 2005; Lim et al., 2010):  
1. Collagenases (MMP-1, -8, -13, -18)  
2. Gelatinases (MMP-2, -9) 
3. Stromelysins (MMP-3, -10, 11)   
4. Matrilysins (MMP-7, -26)  
5. Membrane-type MMPs (MT-1, -2, -3, -4, -5)  
6. Other MMPs (e.g. MMP-12, -19, -22)  
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 Figure 1.9. Domain structures of matrix metalloproteinases (MMPs). MMPs are multidomain 
proteases that contain a pro-domain, an active domain, a zinc-binding domain and a heamopexin 
domain. The characteristic of the MMP family is the catalytic site that contains the zinc-binding 
domain. MMPs can be divided into 6 different groups depending on their substrate specificity. 
Gelatinases (MMP-2 and MMP-9) contain a gelatin-binding domain with three fibronectin-like 
repeats. MMP-9 comprises a serine-, threonine-, and proline rich O-glycosylated domain, and both 
MMP-2 and MMP-9 can be N-glycosylated. The majority of MMPs are secreted in a latent pro-form. 
The removal of the pro-peptide (about 10 kDa), results in enzyme activation (Figure is from Hu et al., 
2007). 
The substrate specificity of MMPs is broad. MMPs are able to degrade approximately all 
components of ECM and thus affect the turnover of this compartment. These enzymes are 
also involved in several other physiological and pathological processes, such as wound 
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healing, inflammation, development and reproduction, and tumour metastasis (Hadler-Olsen 
et al., 2011; Kadoglou et al., 2005; Manon-Jensen et al., 2010). It has been suggested that 
MMPs in blood can be used as potential markers for vascular changes in diabetes 
(Gharagozlian et al., 2009)  
 
 1.9.1 Regulation and activation of MMPs 
MMP activity is rigidly controlled at 4 different levels, including (1) gene transcription, (2) 
activation, (3) inhibition by the TIMPs (Kadoglou et al., 2005), and (4) compartmentalization 
(Ra & Parks, 2007; Hadler Olsen et al., 2011). A broad range of inflammatory cytokines, 
growth factors and tumour promoters such as interleukin-6, platelet-derived growth factor 
(PDGF), epidermal growth factor (EGF) and TNF-α, can induce MMP transcription (Hu et 
al., 2007; Kadoglou et al., 2005). All MMPs with the exception of MT-MMPs are zymogens, 
meaning they are secreted in a latent pro-form (Chakrabarti & Patel, 2005). In this inactive 
form, a cysteine sulphydryl group in amino-terminal prodomain interacts with a zinc ion and 
blocks the active site of the enzyme. Activation of the enzymes occurs in extracellular space 
and is instigated by other proteases such as other MMPs (particularly membrane-type MMPs), 
elastase or trypsin. Furthermore, MMP activity is also regulated by TIMPs, which act by 
binding reversibly to latent or active forms of MMPs. The binding of TIMPs blocks the access 
of substrates to the catalytic site, and thereby inhibits their enzyme activity. There are four 
known types of TIMPs (TIMP-1-4), each with varying specificity for the different types of 
MMPs  (Hu et al., 2007). Compartmentalization describes where and how in the intracellular 
compartments MMPs are stored and released, and is important for regulating enzyme activity. 
Based on their motifs and modules, the secreted MMPs are directed to various destinations in 
the extracellular environment including cell membranes. MMPs can then bind to collagens, 
laminins, fibronectins, core-proteins and GAG chains of proteoglycans. 
Compartmentalization regulates MMP activity based on location and by concentrating them 
close to potential substrates (Ra & Parks, 2007; Hadler-Olsen et al., 2011).  
The two gelatinases A and B (MMP-2 and MMP-9 respectively) are the most significant 
MMPs in normal kidneys and are thus believed to play vital roles in basement membrane and 
mesangial matrix homeostasis. Both enzymes are able to break down basement membrane 
collagens and gelatines, however, their substrate specificity is not identical. MMP-2 degrades 
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fibronectin and laminin, and has considerably lower activity against types IV and V collagen 
than MMP-9 (Hadler-Olsen et al., 2011). Moreover, these enzymes differ significantly in their 
promoter structure and therefore also in their expression pattern. MMP-2 and MMP-9 arrange 
in complexes with their tissue inhibitors, TIMP-2 and TIMP-1, respectively (Lenz et al., 
2000). MMP-2 and MMP-9 are secreted as 72 kDa and 92 kDa pro-forms, respectively.  They 
are cleaved into their corresponding active forms: 64 kDa (MMP2) and 83 kDa (MMP-9). 
MMP-2 is secreted from a variety of cell such as endothelial cells and macrophages, while 
MMP-9 is mainly produced by neutrophils and eosinophils. However, inflammatory 
stimulation may induce increased expression of MMP-9 in other cell types such as endothelial 
cell, macrophages and fibroblasts (Chakrabarti & Patel, 2005). 
 
1.9.2 MMP and diabetic nephropathy 
Hyperglycemia has been shown to trigger signalling cascades leading to a disruption of the 
balance between ECM synthesis and degradation (Ban & Twigg, 2008). The ECM in the 
basement membrane of the kidney glomeruli is especially significant for filtration properties. 
Structural modifications in mesangial and basement matrix are associated with proteinuria 
and hypertension and hence, the development of diabetic nephropathy (Gharagozlian et al., 
2009). The two enzyme families MMPs and TIMPs play an important role in vascular 
remodelling of the basement membrane components (Tsilibary, 2003; Lenz et al., 2000). 
Changes in MMP activity is proposed to be a crucial contributing factor in the pathogenesis of 
diabetic nephropathy (Thrailkil et al., 2009; Roy et al., 2009). Thickening of the glomerular 
basement membrane takes places early after the onset of diabetes and may gradually develop 
into diabetic nephropathy (Tsilibary, 2003; Roy et al., 2009). The excess build-up of 
basement membrane components is a consequence of an up-regulated synthesis and a reduced 
degradation under hyperglycaemic conditions (Tsilibary, 2003). Thus, the regulation of 
MMPs is crucial for understanding the different physiological processes and pathogenesis of 
diseases, along with the development of new specific MMP target drugs, which may be a 
useful treatment strategy for diabetes and atherosclerosis (Hadler-Olsen et al., 2011; Death et 
al., 2003).  
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2   Aims 
The main goal of the current thesis was to study the biological effect of hyperglycemia on 
human endothelial cells. The intention of my investigations was to study factors that may 
play a role in matrix changes observed during the development of diabetic nephropathy. 
MMP-2 and MMP-9 have been identified as the most important metalloproteinases in the 
kidney, regulating the turnover of the extracellular matrix in the basement membrane. 
Many of the systemic changes and those seen in the kidneys involve changes in the 
endothelial cells and in particular the development of endothelial dysfunction. In addition, 
the hexosamine pathway has been suggested to play a role in the development of 
endothelial dysfunction in relation to hyperglycemia. To study matrix changes in further 
detail, primary human endothelial cells were used in this study and grown on traditional 
plastic wells and on semipermeable filters. 
 
 
Specific aims: 
1. To study whether hyperglycemia will affect synthesis and secretion of MMP in human 
umbilical vein endothelial cells (HUVEC).  
2. To study if the hexosamine pathway is involved in the regulation of MMP secretion in 
endothelial cells using the inhibitor DON, to interfere with this pathway.  
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3   Methods 
3.1 MCDB Medium 
There are different types of MCDB medium, which each have been formulated to provide 
optimal growth for specific cell lines. MCDB-131 media has been developed specifically to 
culture human microvascular endothelial cells, including HUVEC (Sigma-Aldrich, 2011). 
 
Preparation of MCDB-131 medium 
One container of MCDB-131 powder  (11.6 g) was dissolved in 850 ml of MQ-H2O and 1.18 
g of sodium hydrogen carbonate (NaHCO3) was added to the solution. The pH was adjusted 
to 7.3 while stirring. The final volume was adjusted to 1000 ml by adding MQ-H2O. The 
medium was sterile filtered into two 500 ml flasks, using a sterile filter flask with a 0.22 µm 
pore size. Antibiotics, growth factors and FCS (fetal calf serum) were added to 500 ml of 
medium, as listed below in Table 3.1. 
Table 3.1 Components added to the MCDB-131 medium 
Components (Concentration) Amount 
FGF (10 µg/ml): 50 µl 
Hydrocortisone (10 mg/ml) 50 µl 
EGF (10 µg/ ml): 500 µl 
Gentamicine (50 µg/ml) 500 µl 
Fungizone (250 µg/ ml) 500 µl 
FCS (7%) (Heat inactivated) 37.5 ml 
 
 
24 
 
3.2. Isolation of Human Umbilical Vein Endothelial 
Cells (HUVEC) 
HUVEC are primary endothelial cells isolated from the vein of the human umbilical cord. The 
method was first developed by Jaffe and Nachman in 1973 (Jaffe et al., 1973). HUVEC is 
used as a model for endothelial cells for a large community of researchers all around the 
world (Baudin et al., 2007). 
HUVEC were obtained fresh from the obstetric and gynaecology division, Rikshospitalet, 
Oslo. Written consent was acquired from the mothers and ethical approval was obtained from 
the Human Research Ethical Committee.  
 
Procedure 
HUVEC were isolated from the vein of the umbilical cord (Figure 3.1) by an adjustment of 
the method by Jaffe et al. (1973). The isolation of the endothelial cells was carried out under 
sterile conditions. Immediately after delivery, the umbilical cord was placed in a sterile 
container filled with transport buffer (Appendix I Table 8.5.0). The cord was kept in the 
fridge at 4°C for a maximum of 24 h before isolation. Damaged tissue was removed and the 
vein was rinsed with phosphate buffered saline (PBS) (Table 8.5.2) in order to remove any 
remaining blood. Thereafter, the cord was incubated with 10 ml of 0.2% collagenase (Table 
8.5.3) for 10 min, at 37°C in order to isolate the endothelial cells from the vein. The cell 
solution was centrifuged at 1500 rpm for 10 min. The cell pellet was resuspended in 15 ml of 
complete MCDB-131-medium, transferred to a 75 cm2 cell culture flask and incubated at 
37°C in a humidified 5% CO2 atmosphere. The culture medium was changed the following 
day in order to remove remaining blood cells.  
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Figure 3.1. HUVEC were 
isolated from the vein of the 
umbilical cord under sterile 
conditions. The figure 
demonstrates a cross-section of 
an umbilical cord displaying the 
vein and its two arteries (Figure 
is taken from Helgason & 
Miller, 2005) 
 
3.2.1 Polarization of HUVEC 
Polarized HUVEC culture is a useful method for studying endothelial cells, as the cells are 
able to secrete proteins into both the apical (towards lumen) and the basolateral medium 
(towards VSMC), in a near in vivo condition. To obtain polarization, HUVEC were cultured 
on 12-well Costar Transwell clear polyester membrane filter inserts, with a 0.4µm pore size 
(Figure 3.2). The filter plates were incubated with MCDB-131 medium containing FCS, 1-16 
h in advance of HUVEC culture, in order to coat the membrane with plasma proteins. 
 
 
Figure 3.2. Illustration of 
one well filter inserts for 
culturing polarized cells. 
The illustration is based on 
image from Rosengren et 
al., 1991 
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3.3 Culture of HUVEC 
Cells were cultured at 37°C in 5% CO2, in complete MCDB-131 medium, containing 7% 
FCS. Cells were either cultured on traditional plastic plates or on filter plates. The medium 
was changed every second day, using 15 ml for a 75 cm2 flask. Only cells from passages 2-4 
were used in experiments, due to the risk of changes in phenotype in cells from higher 
passages (Cheung, 2007). Cells were split when they had reached a confluence of about 80%, 
which constitute approximately 50-100 000 cells per cm2 (Figure 3.3) Cells were therefore 
regularly monitored in the microscope. Cells were split approximately 1-2 times per week, 
depending on their growth. HUVEC were washed with 5 ml of PBS to remove serum, as 
serum inhibits the action of trypsin. Next, the cells were incubated in 4 ml of trypsin for 
approximately 2-5 min, in order for the cells to loose surface contact. Detached cells were 
observed as round shapes as opposed to the long shape of the attached endothelial cell. Fresh 
complete medium (4 ml) was added in order to deactivate the trypsin. The cells were 
transferred into a falcon tube and pelleted at 1300 rpm, for 3 min at room temperature and 
resuspended in a desired volume of complete medium before transferring to flasks or wells. 
The cells were split in a 1:3 ratio.  
 
Figure 3.3. The image shows a phase-
contrast micrograph of a confluent 
monolayer of HUVEC (Figure taken 
from Helgason & Miller, 2005) 
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3.4 General experimental outline 
HUVEC were cultured on conventional plastic plates (6 or 12 wells), in cell culture flasks for 
Western analysis and on filter plates (12 wells). HUVEC were grown in 2 ml medium for 
each well of the 6-well plate and in 1 ml of the 12-well plastic plate. In the polarized 
experiments, 1 ml of medium was loaded in the basolateral well, while 0.5 ml of medium was 
loaded apically (Figure 3.2). 
When cells had reached a confluence of more than 80 % on plastic and 100 % on filter, they 
were exposed to various concentrations of glucose (5, 15, 25, and 40 mM) or DON (50, and 
100 µM) for a certain amount of time (usually 24 h). Normoglucose (5 mM, without DON) 
was used as a control in all experiments. The baseline medium already contained a glucose 
concentration of 5 mM and therefore had to be taken into account when calculating 
concentrations. Cells were washed and cultured in serum-free MCDB-medium for the last 24 
h, to avoid proteases from the serum to obstruct the results.  
 
3.5 Harvesting of medium 
The conditioned medium (1 ml) was transferred to Eppendorf tubes containing 100 µl of 100 
mM CaCl2 and 100 µl of 1 M Hepes, while working on ice. Hepes and CaCl2 were added to 
the samples in order to stabilize the MMP and avoid degradation of the proteins when 
freezing and thawing the samples. Ca2+ stabilizes the active seat of MMP, while Hepes 
regulates the pH. The samples were spun at 10 000 rpm for 10 minutes at 4°C, to remove cells 
and allocated to new Eppendorf tubes, and immediately kept in the freezer at -20°C.  
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3.6 Lysis of HUVEC 
Cell lysis is the method by which a cell is broken down as a result of some external force or 
treatment. The remaining substance consists of the destroyed cells and is referred to as the 
lysate. The purpose of cell disruption is to release the intracellular proteins. Radio-
Immunoprecipitation assay (RIPA) (Table 3.6) is used for cell lysis and protein solubilisation 
while avoiding protein degradation. 250 µl of complete RIPA buffer was added to each well, 
for the 12 well plastic plate, while 170 µl of RIPA was added to each well when using the 
semi-permeable 12-well filter plates. The cells were scraped from the wells in ice-cold 
complete RIPA buffer. Samples were allocated to Eppendorf tubes and placed on ice for 30 
min and were tapped approximately every 10 minutes. The whole cell lysates were 
centrifuged at 10 000 rpm, for 10 min, at 4˚C, in order to remove cell debris. The supernatants 
were allocated to new Eppendorf tubes and frozen down at -20˚C until protein quantification 
was carried out. 
Table 3.6 Complete RIPA buffer 
Components Final concentration 
Tris HCl pH 7.4 0.05 M 
NaCl 0.15 M 
Triton X-100 1% 
SDS 0.1 % 
Natriumdeoxycholate 0.5 % 
EDTA 1 mM 
Natriumpyrophosphate  10 mM 
1 protease-inhibitor tablet pr 10 ml RIPA added right before use. 
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3.7 Protein Quantification 
Principle 
The Bicinchoninic Acid (BCA) assay is a biochemical technique used to determine the 
protein concentration in a solution. The colour solution indicates the total protein 
concentration within a sample, as it switches from green to purple. This can be measured by 
colorimetric methods. The BCA assay is based on two principle reactions. Firstly, the peptide 
bonds in proteins reduce Cu2+ ions from the cupric sulphate to Cu1+ (a temperature dependent 
reaction). The amount of Cu2+ reduced is comparable to the quantity of protein in the sample. 
Secondly, two molecules of bicinchoninic acid chelate with each Cu1+ creating a purple 
coloured product that efficiently absorbs light at a wavelength of 562 nm (Thermo Fisher 
Scientific, 2011; Olsen & Markwell, 2007).  
 
Procedure for determining protein concentrations 
A standard curve was prepared and plotted based on a BSA stock solution (2 mg/ ml). RIPA 
buffer was added to the standards (20 µl to each well) in order to adjust for potential effects of 
the RIPA buffer in the samples (Table 3.7). In this way, standards and samples were treated 
as similar as possible. 
In each well 20 µl of sample, 30 µl of MQ-H2O and 200 µl of A + B solution was added. 
Triplicates were made for each sample. The A+B solution was made from 98% of micro 
reagent A and 2% of micro reagent B. The microtiter plate was incubated at 37ºC for 30 min. 
The absorbance was measured at wavelength of 562 nm, using the Titertec Multiscan 
spectrophotometer. A standard curve was made, plotting the absorbance (Y-axis) versus the 
known protein concentrations (X-axis). The unknown protein concentrations were calculated 
using the standard curve, taking dilutions into account.  
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Table 3.7. Standard samples 
Well BSA (2mg/ml) MQ-H2O Lysis buffer A+B solution 
A 0 µl 30 µl 20 µl 200 µl 
B 0 µl 30 µl 20 µl 200 µl 
C 3 µl 27 µl 20 µl 200 µl 
D 3 µl 27 µl 20 µl 200 µl 
E 5 µl 25 µl 20 µl 200 µl 
F 5 µl 25 µl 20 µl 200 µl 
G 8 µl 22 µl 20 µl 200 µl 
H 8 µl 22 µl 20 µl 200 µl 
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 3.8 Gelatin zymography 
 Principle 
Zymography is an electrophoretic technique used for measuring enzyme activity and is widely 
used for studying MMPs. The standard method is based on sodium dodecyl sulphate (SDS) 
gels infused with a protein substrate. The substrate used here was gelatine, as MMP-2 and 
MMP-9 are both able to break down this substrate and can therefore be recognized on gelatine 
zymograms (Troeberg & Nagaese, 2003). In zymography, the gel traditionally consists of 
water, buffer, acrylamide, ammonium persulfate (APS) and tetramethylethylenediamine 
(TEMED). Polymerization is commenced by APS and TEMED. TEMED stimulates the 
formation of free radicals from persulfate and these in turn catalyze polymerization. TEMED 
and APS are therefore added right before loading the gel (Menter, 2000). The samples are 
first loaded into wells of the stacking gel, which has a lower concentration of acrylamide, a 
lower pH and a different ionic content. This enables the proteins in a loaded sample to be 
concentrated into tight bands before entering the resolving part of a gel. The separation gel 
(resolving gel) allows the loaded sample to become fractioned. The gel acts a matrix, 
separating out molecules according to their charge and size. A higher concentration of 
acrylamide will ease the separation of small compounds (Thermo Fisher Scientific, 2011). 
During electrophoresis, SDS causes the MMPs to denature (reducing the protein to its primary 
structure) and become inactive. Following electrophoresis, the gel is washed in a buffer 
(Appendix I Table 8.5.4), to remove the SDS. The enzymes then partially regain their 
activity. Subsequently, the gel is activated in 1x incubation buffer (Table 8.5.5) over night 
and the renatured MMPs in the gel will digest the substrate gelatine. Following incubation, 
the gel is dyed with Coomaisse Blue (Table 8.5.6) and then washed in destaining buffer 
(Table 8.5.7) in order to remove unbound dye, where the MMPs have digested the gelatine. 
Thus, the MMPs are detected as clear bands against a blue background of undegraded 
substrate (Snoek-van Beurden & Von den Hoff, 2005). 
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Procedure 
Gel caster components were wiped clean with ethanol in order to remove any proteins that 
could potentially obstruct the results. The separation gel (Table 8.5.8) was carefully loaded 
between the glass plates of the sandwich stack. MQ-H2O was added in order to obtain a 
straight line on top of the gel. The gel was left at room temperature for 15-20 min for the gel 
to solidify. The water was carefully removed from the top of the gel using filter paper, and 
stacking gel (Table 8.5.9) was loaded. The comb was inserted into the stacking gel in order to 
generate wells. When the gel had stiffened, the gel caster sandwich was removed and placed 
in the electrophoresis apparatus, and 1x running buffer (Table 8.6.1) was poured in. 
Recombinant standards of pro-MMP-2 and pro-MMP-9, and samples containing equal 
amounts of protein, were loaded into each well. Electrophoresis was run at 30-40 mA for 
approximately 2 h when using two gel caster sandwiches, and at 20 mA when only using one. 
Electrophoresis was continued until the blue colour had driven out of the gel. Next, the gel 
was washed with 50 ml of washing buffer (Table 8.5.4) for approximately 45 min, changing 
the buffer once. The gel was incubated in incubation buffer (Table 8.5.5) overnight at 37ºC. 
The gel was dyed using 50 ml of staining solution (Table 8.5.6) for 30-60 min, followed by 
50 ml of destaining solution (Table 8.5.7) for another 45-60 min, changing the buffer once. 
The gel was stored in MQ-H2O and was photographed under normal light. 
 
Quantification 
The intensities of the bands obtained from zymography were quantified using the programme 
Quantity-One (Bio-Rad). The image (Tiff) was imported into the programme and an equal 
sized rectangular square was placed around each gelatinase band, in order to measure the 
intensities (relative units) of the bands.  
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3.9 SDS-PAGE 
In sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE), the protein samples are 
treated with 2-mercaptoethanol to reduce any disulfide bonds. SDS is a powerful anionic 
detergent, which binds to hydrophobic regions of protein molecules denaturing their 
structures, causing the unfolding of polypeptide chains. SDS covers the proteins with an 
overall negative charge. The samples are loaded on a highly cross-linked gel matrix of 
polyacrylamide. Smaller proteins migrate more easily through the gel than bigger proteins. In 
this way, a sample consisting of a complex mixture of proteins is separated into a series of 
distinct protein bands according to size only (Horton et al., 2002; Hames & Hooper, 2002). 
Procedure  
The cell lysates were prepared as indicated earlier, and diluted with RIPA in order to obtain 
equal concentrations of the proteins. 30 µl of sample was mixed with 10 µl of (4x) loading 
buffer (Table 8.6.2). All samples were boiled for 5 min in a heating block and spun quickly 
down. Precast gels (Criterion TM Precast gel, 4-20% Tris HCl) were submerged into the 
electrophoresis apparatus and running buffer (Table 8.6.1) was poured into the container. 
Samples and protein standards were loaded into the indicated wells. The SDS was run at 120 
V for approximately 2 h until the bromphenol blue reached the bottom of the gel.  
 
3.9.1 Western blotting 
Western blot is used to identify specific proteins in a given sample. Proteins are separated by 
size by SDS-PAGE, and are transferred to a membrane. The membrane is blocked in order to 
prevent any nonspecific binding of antibodies to the surface of the membrane. Thereafter, the 
membrane is incubated with a primary antibody specific to the protein of interest. The 
membrane is then incubated with secondary antibody conjugated to horseradish peroxidase 
(HRP). The secondary antibody recognizes the primary antibody. Enhanced 
chemiluminescence (ECL) plus is applied to the blot. The ECL solution contains luminol, 
which is substrate for HRP. Light is produced when luminol is oxidated and the light output 
can be captured on film.  
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 Procedure  
The gel was removed from the electrophoresis apparatus and equilibrated for 15 min in 
blotting-buffer in order to remove remaining SDS. Polyvinylidene fluoride (PVDF)-
membrane and filter papers were cut in the same size as the gel before activating the 
membrane in methanol for 15 sec. The membrane was then equilibrated for 10 min in blotting 
buffer (Appendix I Table 8.6.4). The sandwich cassette was put together in the following 
order (red side of the cassette facing up): 1 sponge, 2 filter papers, PVDF membrane, gel, 2 
filter papers, and 1 sponge. Air bubbles were carefully removed in order not to prevent the 
transfer of proteins to the membrane (Figure 3.9).  
Figure 3.9. Assemble of the cassette 
 
Figure 3.9. Assemble of the cassette. The figure 
shows that the construction of the components. 
The sponge was first soaked in TBST and placed 
on the red side of the cassette, followed by two 
filter papers, the membrane, the gel, two filter 
papers and finally a sponge. 
 
The cassette holding the sandwich stack was inserted in the blotting tank as colour indicated, 
and transfer buffer (Table 8.6.6) was poured into the tank to the fill mark. The transfer buffer 
maintains the conductivity and pH, so that the proteins can easily migrate from the cathode to 
the anode, thus, transfer of proteins from the gel over to the membrane (blotting). A cooling 
agent (ice block) and a stirring bar were added to the tank. The blotting was run at 100 V for 
60 min. 
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Blocking non-specific sites 
The membrane was blocked with 3% BSA (bovine serum albumin) in TBST (Table 8.6.8) 
prior to immunostaining, in order to prevent non-specific binding of antibodies. 
  
Immunostaining/ Detection 
The membrane was incubated with a primary antibody diluted in TBST at 4°C over night at 
an agitator. The membrane was then rinsed 3 x 5 min in TBST in order to remove any 
unbound primary antibody. Next, the membrane was incubated with a HRP-conjugated 
secondary antibody (Appendix I) diluted in TBST for 60 min at room temperature, before 
removing unbound secondary antibodies by washing 3 x 5 min in TBST. 
 
Development 
The membrane was incubated with ECL (plus) solution for 5 minutes and placed in a 
HypercassetteTM. Light produced was captured on a film and the image developed using 
Hyperprocessor Amersham Pharmacia biotech developer. 
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4 Results 
Endothelial cells are the first cells to be exposed to hyperglycemia in type 1 and type 2 DM. 
Elevated blood glucose levels may lead to endothelial dysfunction and promote inflammatory 
reactions in these cells (Brownlee, 2005). To investigate the effects of hyperglycemia on the 
endothelium we used primary cultures of endothelial cells isolated from human umbilical 
cords. MMP-2 and MMP-9 were used as targets to investigate possible effects of 
hyperglycemia, due to the importance of these enzymes in both diabetes related inflammation 
and fibrosis. HUVEC were exposed to normo- (5 mM) and hyperglycemic (25 mM) 
conditions and the effects on MMP secretion were studied. In addition, the possible 
importance of the hexosamine pathway for effects of hyperglycemia on HUVEC was 
investigated using DON, an inhibitor of the enzyme GFAT. 
 
4.1 Effect of hyperglycemia on protein synthesis 
The initial experiments were performed to measure possible effects of hyperglycemia on 
protein synthesis as a marker for general condition of the cells. HUVEC were cultured in 
conventional plastic and exposed to four different concentrations of glucose (5 mM, 15 mM, 
25 mM, and 40 mM) in serum-free media for 24 h. Serum-free medium was used due to high 
levels of MMPs in serum. Protein concentration was measured in the cell lysates. Protein 
synthesis increased slightly with increasing glucose concentrations, up to 25 mM and then 
decreased with the highest concentration (40 mM), as can be seen in Figure 4.1. The same 
trend has been observed in a second experiment with cells obtained from another umbilical 
cord (Appendix II Figure 9.1).  
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Figure 4.1. Protein synthesis in response to glucose concentrations. HUVEC were cultured with 
different glucose concentrations (5 mM, 15 mM, 25 mM, and 40 mM) for 24 h in serum-free media. 
Results presented are from cell fractions originating from three separate wells.  
 
4.2 Effect of hyperglycemia on gelatinase secretion 
The purpose of the next experiment was to study the effect of varying glucose concentrations 
on gelatinase secretion from HUVEC. The cells were obtained from two different donors and 
incubated with 4 different concentrations of glucose (5 mM, 15 mM, 25 mM and 40 mM) for 
24 h. Medium samples with equal protein concentrations were subjected to zymography to 
measure possible gelatinase activities. The most prominent bands observed, and in most cases 
the only band observed in the zymography gel, migrated as the pro-MMP-2 (72 kDa) 
standard, as can be seen in Figure 4.2A. There was a greater gelatinase activity obtained from 
medium of cells from donor 1 cultured under NG conditions (5 mM) compared to HUVEC 
exposed to higher concentrations. This trend was also seen in medium obtained from cells 
from donor 2 (Figure 4.2A). The intensity of each band was measured (Figure 4.2B). These 
analyses clearly demonstrated that gelatinase activity decreased when increasing the glucose 
concentration from 5 to 15 mM. Above this concentration there was a variation in effect 
between the two different HUVEC preparations used. No gelatinase activity was observed 
that co-migrated with the pro-MMP-9 standard in medium obtained from both donors. To 
further confirm that HUVEC released MMP-2, conditoned medium was subjected to Western 
blotting, which showed that bands from both NG and HG media are indeed MMP-2 (Figure 
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4.2C). In addition, a metalloproteinase inhibitor, ethylenediaminetetraacetic acid (EDTA) was 
used in parallel zymography experiment. Using this chelator showed a complete abolishment 
of gelatinase activities (not shown), demonstrating that the enzyme activity observed in 
zymography experiments is of metalloproteinase nature.  
 
Figure 4.2. A. Gelatinase secretion from HUVEC. Zymography was performed on medium obtained 
from two HUVEC donors. HUVEC were cultured with different glucose concentrations (5 mM, 15 
mM, 25 mM, 40 mM) for 24 h. The medium samples with equal protein concentrations were loaded 
and separated in a 4-7.5 % SDS-gel. Figure 4.2.B. Quantification of bands from the zymography in 
Figure 2A. Donor 1 shows a higher secretion of pro-MMP-2 in 5 mM compared to 25 mM (306.6 % 
change). Donor 2 shows a higher secretion of pro-MMP-2 compared to 25 mM (7.9 % change). 
Figure 4.2.C. Immunoblot on medium samples from HUVEC cultured with NG for 24 h using an 
anti-human MMP-2 polyclonal antibody, which recognized both latent and active forms of MMP-2. In 
this case, only the pro-form of MMP-2 was visible (72 kDa). 
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4.3 Effect of hyperglycemia and time of incubation on gelatinase 
secretion 
Furthermore, it was of interest to investigate the effects of hyperglycemia and duration on 
gelatinase secretion. HUVEC were incubated with 4 different concentrations of glucose (5 
mM, 15 mM, 25 mM and 40 mM). Cells were harvested 2, 6 and 24 h after incubation under 
serum-free conditions and subjected to zymography. The results from the zymography 
indicate that pro-MMP-2 secretion increased with longer incubation time. In addition, there 
was a greater activity at NG (5 mM) compared to higher glucose concentrations at 6 h and 24 
h. Accordingly there is a decrease in pro-MMP-2 secretion with increasing concentrations of 
glucose (Figure 4.3A).  The intensity of the bands was measured (Figure 4.3B), which 
confirmed that the there is a higher activity of pro-MMP-2 at 5 mM after 6 h, compared to the 
higher concentrations of glucose. After 24 h, the expression of pro-MMP-2 is greater at 5mM 
compared to 25 mM and 40 mM of glucose, but not 15 mM. Again, no bands were observed 
with activity migrating as the pro-MMP-9 standard. These results show the same trend as the 
findings in Figure 4.2. Experiments were also performed up to 8 and 14 days in order to 
investigate the effect of MMP-2 secretion over longer time periods. The results varied, but 
indicated a greater secretion of pro-MMP-2 in the HG condition opposed to NG, giving 
contradictory results (Table 4.1). 
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Figure 4.3A.  Zymography of medium from HUVEC exposed to various glucose concentrations (5 
mM, 15 mM, 25 mM, 40 mM) for 2, 6 and 24 h. Medium samples were adjusted for protein 
concentrations, and equal concentrations were loaded into each well (Figure 3A). Figure 4.3B. 
Quantification of bands from Figure 4.3A.  
 
A total of six experiments were performed on plastic with HUVEC from different donors. 
There are conflicting results regarding the secretion of pro-MMP-2 under NG and HG. Four 
of the experiments showed higher pro-MMP-2 activity under NG, while two other 
experiments showed increased activity of pro-MMP-2 under HG conditions (Table 4.1). All 
together the experiments on plastic indicate pro-MMP-2 secretion is most potent at NG than 
at HG. 
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Table 4.1. Experiments conducted on plastic 
Experiment*, 24 h incubation Demonstrated number of times % Change increase 
Secreted MMP-2 is highest in 
 5 mM glucose 
4 306.6 
41.1 
7.9 
3.7 
Secreted MMP-2 is highest in 
 25 mM glucose 
2 24.2 
18.4 
 
*The experiments indicated in the table are from different donors.  
 
4.4 Effect of hyperglycemia and incubation time on polarized 
HUVEC 
HUVEC were also grown on semipermeable filters in order to analyze if there was a polarized 
secretion of MMP-2 and MMP-9 from cultured HUVEC, and to investigate if there was a 
time-dependent effect on MMP secretion, under NG and HG conditions. Considering that 
endothelial cells operate as polarized cells, filter experiments are useful supplements to 
experiments performed on conventional plastic. Such a system allows comparative analyses 
of secretion to the apical and basolateral side of the endothelium with obvious relevance to 
the in vivo situation. 
 
Figure 4.4 Zymography of secreted pro-MMP-2 in apical- and basolateral medium from HUVEC 
incubated with NG (5 mM) and HG (25 mM), for 2, 6, and 24 h.  
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Figure 4.4 shows that the secretion of pro-MMP-2 increased in a time dependent manner with 
highest secretion after 24 h incubation with NG and HG. There is a polarized secretion with 
more pro-MMP-2 being secreted to the apical side than to the basal side, as the bands detected 
for the basolateral medium were much weaker than the apical bands. These results were 
confirmed in a second experiment using HUVEC from another umbilical cord (results not 
shown). 
Furthermore, the results suggest that there is a stronger secretion of pro-MMP-2 from cells 
incubated with HG compared to NG in the apical medium, when comparing secretion after 2 
and 6 h. However, the secretion of pro-MMP-2 appears to level off after 24 h of incubation, 
showing no great difference between the NG and HG. However, the quantification analyses 
indicated a greater secretion under NG conditions, with a 4.5 % increase in pro-MMP-2 
secretion in the NG state. This increase is probably neglible. No bands co-migrating with the 
pro-MMP-9 standard could be detected. All together, four experiments were performed on 
filter, using HUVEC from different donors, in which no clear trend was found (Table 4.2). 
Two experiments showed a clear increase in pro-MMP-2 activity under HG conditions in the 
apical medium, whereas two experiments showed a higher secretion under NG conditions (in 
the apical medium). 
 
Table 4.2 Experiments conducted on filter 
Experiment*, 24 h incubation Demonstrated number of times % Change increase 
Secreted MMP-2 is highest in 5 
mM glucose 
2 140.1 
3.3 
Secreted MMP-2 is highest in 
25 mM glucose 
2 212.5 
33.1 
*The experiments are from different donors. 
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4.5 Effect of DON on MMP secretion 
HUVEC were isolated and cultured on plastic plates. Cells were exposed to NG or HG using 
different concentrations of DON (50 and 100 µM). Cells and medium frations were harvested 
after 24 h. A zymography was performed in order to analyze the enzyme activity of MMP-2 
and MMP-9. Under NG conditions, increased DON concentration, (from 0 to 100 µM) caused 
a small reduction in pro-MMP-2 secretion (Figure 4.5A). (The intensity measurements are 
presented in Appendix II Figure 9.2).  The same trend was observed for cells cultured under 
HG conditions. No gelatinase activities corresponding to pro-MMP-9 were observed in any of 
these experiments. Western blot was performed in order to investigate the effects of DON on 
the level of O-GlcNAcylated proteins. Whole cell extracts were analyzed by Western blotting 
using the monoclonal antibody CTD 110.6. The immunoblot shows that the level of O-
GlcNAcylated proteins is increased when HUVEC was exposed to 100 µM DON under NG. 
(Figure 4.5B). However, the glycosylation appears to be decreased under HG conditions (the 
experiment has been reproduced with HUVEC from another umbilical cord, not shown). 
Moreover, the Western blot also indicates that the level of O-GlcNAcylated protein is 
increased from NG to HG in the control (0 µM DON). 
 
Figure 4.5A. Zymography of secreted pro-MMP-2 in medium from HUVEC cultured with NG (5 
mM) and HG (25 mM) together with different concentrations of DON (0, 50, and 100 µM). Figure 
4.5B. Western blot of whole cell extracts from HUVEC stimulated with NG (5 mM) and HG (25 mM) 
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and different DON concentrations (0 µM, 50 µM, 100 µM). The monoclonal antibody CTD 110.6 was 
used to detect O-GlcNAcylated proteins. 
 
4.6 Effect of DON on polarized cells 
Experiments using DON as an inhibitor were also carried out on polarized cells, in order to 
observe if DON treatment gave a similar effect on filter as on plastic. Cells were exposed to 
50 and 100 µM of DON and were incubated with either NG or HG for 24 h. MMP activity for 
the apical medium fractions was analyzed by zymography. No bands were detected for pro-
MMP-9 (Figure. 4.6). Intensities of the bands have been quantified (Appendix II Figure 
9.3). 
 
Figure 4.6. Zymography of secreted pro-MMP-2 in apical medium from HUVEC incubated with NG 
and HG and various concentrations of DON (50 and 100 µM) for 24 h.  
 
There was a polarized secretion from endothelial cells grown on filter. The secretion of pro-
MMP-2 was strongest to the apical side of medium. The bands in the basolateral medium 
were too weak to be quantified. Under NG conditions, pro-MMP-2 secretion is decreased 
with higher concentrations of DON (50 and 100 µM). In the HG state, pro-MMP-2 secretion 
is also decreased when exposed to 50 µM of DON. However, pro-MMP-2 seems to increase 
with 100 µM DON under HG conditions, suggesting that the highest concentration of DON 
does not give consistent results.  
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5 Discussion 
In the present thesis, the effect of HG on MMP secretion from HUVEC was investigated. 
Secondly, the involvement of the hexosamine pathway on MMP secretion was studied. 
HUVEC were exposed to HG (25 mM) to mimic diabetes in vitro. NG (5 mM) was used as a 
control. These concentrations were chosen as they have been widely used in previous 
experimental short-term diabetes studies in vitro (Garaghozlian et al., 2006; Death et al., 
2003). 5 mM is near the normal glucose range (3.6 -5.8 mM) kept in healthy, non-diabetic 
humans. Although 15 mM is closer to the diagnostic value of diabetes (> 11 mM after intake 
of 75 g of anhydrous glucose), a greater difference in MMP expression was seen between 5 
and 25 mM in the experiments presented in this thesis (Figure 4.2 and 4.3). Furthermore, 
Figure 4.1 depicts that there is greater difference in protein synthesis between 5 and 25 mM, 
rather than 5 and 15 mM.  
 
5.1 Major findings: Effects of hyperglycemia on MMP secretion 
on plastic and filter 
In the current investigation, a total of six experiments were carried out on plastic exposing 
HUVEC to NG and HG for 24 h. Four of these experiments demonstrated that secretion of 
MMP-2 was reduced in HUVEC exposed to HG. However, the opposite was found in two 
other experiments, in which MMP-2 secretion was increased in HG compared to NG (Table 
4.1). Overall, these investigations indicate a weak trend showing that MMP-2 secretion is 
decreased when exposed to HG.  
Tram Thu Vuong, a member of the lab (personal communication), also studied the effect of 
HG on MMP-2 secretion under the same conditions. In these four experiments carried out the 
secretion of MMP-2 was lower at HG compared to NG (unpublished data). This is in 
agreement with the weak trend in my findings. Available literature regarding MMP-2 
secretion from endothelial cells is conflicting. Similar to my findings on plastic, Gharagozlian 
et al. (2006) found that MMP-2 secretion was reduced in cultured HUVEC exposed to HG 
(25 mM) conditions compared to controls (5 mM). In contrast, Death et al. (2003) showed 
that there was a significant increase in expression of MMP-2 in HUVEC exposed to HG (25 
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mM). Likewise, Ho et al. (2007) discovered that MMP-2 was elevated in HUVEC culture 
after treatment with HG (33 mM). To my best knowledge, there are very few reports 
regarding the secretion of MMP-2 from HUVEC under HG conditions. Other studies that 
have addressed MMP secretion under HG, involve different cell types. McLannen et al. 
(2000) found that HG (25 mM) decreased MMP-2 activity in isolated human mesangial cells, 
suggesting that HG reduced breakdown of the mesangium matrix, due to a down regulation of 
MMP activities. Anderson et al. (1996) studied the effect of HG (25 mM) on MMP-2 
secretion in mesangial cells. He also found that the level of MMP-2 secretion was reduced 
under HG conditions compared to NG (5 mM). 
In the present study, HUVEC were also cultured in a polarized fashion, exposing cells to NG 
and HG for 24 h. Culture of polarized cells is a useful method for studying HUVEC, as the 
cells secrete proteins into the luminal and basal side of the filter, mimicking the in vivo state 
(Cole-Parmer, 2011). Variable results were found in the four experiments conducted on filter 
(Table 4.2). More experiments were undertaken, but the gelatinase activities were too weak to 
be measured and these experiments were therefore not included in this thesis. Two 
experiments showed a higher secretion of MMP-2 under NG conditions compared to HG 
(Figure 4.4 and 4.6), which is consistent with the weak trend observed for experiments 
conducted on plastic plates. However, the opposite was found in two other experiments, 
demonstrating a greater secretion of MMP-2 at HG compared to NG (results are not shown). 
The culture of polarized HUVEC is not a widely established method and there are a limited 
number of studies using this system. No trend was discovered in the filter experiments 
conducted by other members of the research group (Vuoung, unpublished data). More 
experiments on filter are needed in order to conclude on the effects of HG on polarized 
HUVEC.  
The experiments using polarized HUVEC revealed a greater secretion of MMP-2 to the apical 
compartment (Figure 4.4 and 4.6). Other reports have also found MMP secretion to be 
greater to the apical side of the cells compared to the basal side (Martin et al., 2000). The 
reason behind the predominantly apical secretion is not known. A higher secretion to the 
apical side may be conflicting with the hypothesis that basement membrane components are 
primary targets of MMP in HUVEC. However, the secretion to the apical side may potentially 
target the MT-MMPs. MT-MMPs form a heterotrimeric complex with MMP-2 and TIMP-2, 
resulting in the cleavage of the 72-kDa pro-MMP-2, to 67-kDa its active form (Martin et al., 
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2000). In the current study the majority of MMP-2 was released in its inactive pro-form. 
Secretion of MMPs to the apical side of the cells has also been proposed to be involved in the 
degradation of tight junction of cells, which may result in impaired endothelial barrier 
function (Leone et al., 2007) and vascular functions, such as platelet aggregation and 
vasoconstriction (Sawicki et al., 2000). MMP can also be involved in inflammatory reactions 
through shedding of components of the glycocalyx such as cell surface proteoglycans of the 
syndecan type (Manon-Jensen, 2010). 
There are a limited number of studies that have been conducted regarding MMP secretion 
from vascular cells in vitro. Other reports focus on plasma MMP levels in diabetics, in which 
the majority of these studies point to an increase in MMP-2 levels in plasma in diabetic 
subjects. A study conducted by Gharagozlian et al. (2009) analyzed serum MMP-2 and 
MMP-9 from diabetic patients and healthy controls. The results showed significant higher 
serum levels of both MMP-2 and MMP-9 in diabetic patients compared to healthy controls. 
Thrailkill et al. (2007) found that urine and plasma levels of MMP-2 were significantly 
increased in type 1 diabetic patients compared with healthy control subjects. Similarly, Lee et 
al. (2005) found that levels of MMP-2 concentrations were increased in type 2 diabetic 
patients. Derosa et al. (2007) also found significantly increased plasma levels of MMP-2 and 
MMP-9 in type 2 diabetic patients compared to healthy subjects. Out of all studies found 
conducted on humans, an increase in MMP-2 was demonstrated in patients with diabetes. 
However, it is uncertain whether plasma concentrations of MMP and TIMP indicate their 
corresponding enzyme activity in the vascular wall (Kadoglou et al., 2005). Considering that 
MMPs are important effectors and regulators of inflammation, it is possible that increased 
levels of MMP-2 and MMP-9 in serum of diabetic patients arise due to a higher secretion of 
MMPs from immune cells into the blood. Inflammatory cells including macrophages, 
neutrophils, mast cells and T-lymphocytes are major sources of MMPs and MMP activator 
cells. These inflammatory cells have shown to increase the production of MMP-2 and MMP-9 
from other cells (Singh and Rabbani, 2005; Morgan et al., 2004). In addition to these 
inflammatory mediators, oxidized lipoproteins can promote the expression and activation of 
MMPs (Gharagozlian et al., 2006). Moreover, one must take into the account the effect of 
confounding factors such as diabetes medications, as insulin has shown to increase MMP-2 
activity in rat mesangial cells (Thrailkill et al., 2009).  
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Several studies on rodents have found a reduced expression of MMP-2 activity in renal tissues 
including a higher activity of its inhibitor TIMP-2. However, conflicting results exist as both 
increases and decreases have been demonstrated when rodent mesangial cells have been 
cultured and exposed to hyperglycemic conditions (Thrailkill et al., 2009). An in vitro study 
by Uemura et al. (2001) investigated the effect of HG on bovine aortic endothelial cells 
(BAEC), and found that MMP-9 was increased in HG (25.5) compared to NG (5.5 mM). 
Moreover, they demonstrated that oxidative stress was an important influence on MMP-9 
expression, as enhanced MMP-9 activity was significantly reduced with antioxidant 
treatment.  
In the current study, MMP-9 was either not detected or in few cases the bands were too weak 
to be quantified. Similarly, Gharagozlian et al. (2006) did not observe MMP-9 activity from 
HUVEC. Endothelial cells primarily secrete MMP-1, MMP-2, and MMP-3, while MMP-9 is 
predominantly secreted from macrophages (Death et al., 2003). However, when exposed to 
inflammatory stimulation, secretion of MMP-9 is increased in other cell types, including 
endothelial cells (Chakrabarti & Patel, 2005; Min et al., 2009). Diabetes is described as a low 
inflammatory condition (Stehouwer, 2004). Therefore, it would be interesting to expose 
HUVEC to inflammatory stimulation such as Interleukin-1beta (IL-1β) in addition to HG, in a 
future study to observe the effects on MMP-9 secretion. 
Considering that thickening of basement membrane occurs in HG conditions, a potential 
mechanism underlying this effect is reduced degradation of matrix components, caused by a 
decrease in MMP secretion from endothelial cells or due to an increased expression of 
TIMPs. The findings in the current investigation indicate a lower expression of MMP-2 under 
HG, in HUVEC cultured on plastic, but does not take into the account the effect of TIMP. 
These natural occurring inhibitors may become up-regulated under HG, causing a decreased 
activity of MMP-2 (Thrailkill et al., 2009). Gharagozlian et al. (2006) did not find an altered 
expression in TIMP-1 and -2 by Western blotting, in HUVEC exposed to HG. In a future 
scenario, reverse zymography could possibly reveal if TIMP-2 secretion is increased, 
corresponding to a lower secretion of MMP-2. Another important mechanism in MMP-2 
activation is TGF- β, which has been shown to induce MMP-2 activity (Lenz et al., 2000). 
HG has been shown to increase TGF- β in cell culture, animal models and humans (Zhu et al., 
2007), and may also be a potential focus point for future research.  
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In diabetes, hyperglycemia is strongly linked to accumulation of matrix components, which 
may result in endothelial dysfunction and reduced filtration properties in the kidneys 
(Garagozlian et al., 2006). Previous reports (Thrailkill et al., 2007; Kadoglou et al., 2005) 
indicate a possible correlation between MMP-2 dysregulation and accumulation of ECM in 
diabetes, which may be an instigating factor in complications such as diabetic nephropathy. 
However, evidence appears contradictory (Thrailkill et al., 2007). Thus, a clear role of MMP 
in the progression of diabetes complications and its involvement in the regulation of ECM is 
yet to be established.  
 
5.2 Major findings: Effect of DON and hyperglycemia on MMP 
secretion on plastic and filter 
The hexosamine pathway is considered to play a significant role in the pathogenesis of 
diabetic complications. In the present work, the involvement of this pathway under HG 
conditions was studied, by blocking the rate-limiting enzymatic step in this pathway with the 
inhibitor DON. HUVEC were exposed to different concentrations of DON (50 and 100 µM) 
for 24 h, to study the effect of DON on MMP secretion. HUVEC cultured on plastic showed 
that MMP-2 secretion was attenuated under NG when exposed to 100 µM of DON compared 
to control (0 µM DON) (Figure 4.5A). Under HG conditions a reduction in MMP-2 was 
observed when exposed to both 50 µM and 100 µM of DON compared to control (0 µM 
DON). The same trend was discovered on filter. A reduction in MMP-2 activity was found in 
HUVEC exposed to NG, 50 and 100 µM of DON compared to control (0 µM DON). Under 
HG conditions there was also a reduction in MMP-2 secretion in HUVEC exposed to 50 µM 
but not 100 µM DON (Figure 4.6). 
Overall, the current investigation shows that there is a reduction in MMP-2 secretion in both 
the plastic and filter experiments, when exposing HUVEC to DON. There is no available 
literature regarding the hexosamine pathway and MMP-2 secretion. More experiments are 
needed in order to conclude on the importance of the hexosamine pathway in regulating 
MMP-2 secretion under HG conditions. The mechanism by which blocking GFAT in the 
hexosamine pathway may lead to decreased MMP-2 secretion is currently not known. The 
inhibition of GFAT has been shown to block hyperglycemia-induced increases in the 
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transcription of growth factors central to diabetes (Giacco & Brownlee, 2010). The 
hexosamine pathway may play a crucial role in the pathogenesis of diabetes as it may 
influence cell signalling and MMP secretion.  
The exposure of HUVEC to DON may influence MMP-2 secretion in several ways (Figure 
1.6), as the inhibition of GFAT may alter the biosynthesis pathway (synthesis of 
proteoglycans and glycoproteins) or it may change the expression of MMP-2 via the 
signalling pathway (O-GlcNAcylation) either indirectly by acting on transcription factors, or 
by directly acting on MMP-2. A YinOYang prediction was performed to investigate potential 
O-GlcNAcylated sites of MMP-2. The prediction results showed 4 potential sites for O-
GlcNAcylation attachment sites (Appendix Figure 9.4), indicating MMP-2 as a possible O-
GlcNAcylated target. However, the MMP-2 sequence contains a signal peptide, meaning that 
it is unlikely to contain an O-GlcNAc site. Furthermore, it appears that DON is relatively 
unspecific as it may target several different enzymes and not only GFAT (Pinkus, 1977). 
Therefore one must not exclude the possibility that DON influence MMP secretion through 
other pathways.  
 
5.3 Limitations  
The experiments in this study were all carried out using HUVEC from different donors. 
Individual variation between the donors may explain the variation observed in my results 
(Skliankina et al., 2011). Thus, an increased number of donors are needed in order to establish 
a clear trend. The HUVEC that was received in this project originates from healthy mothers, 
but does not take into account complications during delivery such as caesarean section. 
Trauma during delivery may have affected my results. Further studies could profit from 
comparing endothelial cells with other cells in circulatory system such as monocytes.  
One drawback is the low number of experiments included in this study, although many 
experiments were performed. Unfortunately, many of the experiments conducted on filter 
failed to produce conclusive results, as the bands were too weak to be analyzed and 
quantified. The reason for this observations in several of the polarized HUVEC experiments is 
not known. Perhaps increasing duration of exposure would increase secretion of MMP-2 in 
HUVEC grown on filter, as experiments conducted on plastic with exposure time up to 14 
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days showed a considerable increase in MMP-2 activity (results not shown).  A further 
limitation is that the results from the plastic and filter experiments originate from different 
donors as HUVEC were initially grown on plastic and subsequently on filter. Considering the 
great variation observed in the donors, a different experimental design using the same 
HUVEC donor in parallel experiments conducted on plastic and on filter, may bring clearer 
findings for the effects of HG on MMP secretion in polarized cells. Finally, it is important to 
note the potential restrictions of the programme Quantity-One, seeing that some of 
measurements were not entirely consistent with the visual bands on the images.  
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6  Conclusions 
The present study indicates that HG influence MMP-2 secretion in HUVEC. In the 
experiments conducted on plastic a weak trend was found, showing a reduction in MMP-2 
when exposing HUVEC to HG. Other members of the group have also confirmed this in 
parallel studies. However, some experiments demonstrated the opposite effect, with an 
increase in MMP-2. No trend was found on polarized cells, due to the limited number of 
conclusive experiments. In future experiments it would be interesting to perform experiments 
where comparisons are made between HUVEC obtained from the same donor and cultured 
both on plastic and on filter. This could potentially explain the variations observed in this 
thesis.  
The current work also indicates that MMP-2 secretion in HUVEC grown on plastic is 
attenuated when exposing cells to different concentrations of DON, inhibiting the enzymatic 
step of GFAT. However, more experimental data are needed for clear conclusions. Results on 
secretion of MMP-2 from polarized HUVEC exposed to different concentrations of DON are 
still inconclusive. Before firm conclusions can be drawn, more extensive investigations are 
necessary, particularly studies regarding polarized cells, as this is closer to the in vivo state.  
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8 Appendix I:  
 
8.1 Materials and Equipment 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Amersham Hyperfilm TM ECL GE Healthcare, UK 
Cell culture plastic plates (6, 12 wells) BD Labware, USA 
Cell scraper BD Labware, USA 
Criterion Precast gel (4-20%), 12, 18 wells Bio-Rad, USA 
ELISA microplate (96 wells plate) Greiner bio-one, Germany 
Eppendorf tubes (1.5 ml) Sarstedt, Germany 
Falcon tubes (5ml, 15 ml) BD Labware, USA 
Falcon Pipettes (5, 10, 25 ml) BD Labware 
Hypercasette TM autoradiography cassettes Amersham Biotech, UK 
Immobilon TM Transfer Membrane (PVDF) Millipore, USA 
Messoft Compresses Tendra, Sweden 
Metal Cannulas Technical Department, UIO 
Multiple Gel caster Amersham Biosciences 
Omnifix single use syringes (10, 50 ml) Braun, Germany 
Parafilm  “M”, Laboratory Film American National CanTM, USA 
Pipetboy Integra Biosciences AG, Switzerland 
Single use scalpel Paragon, UK 
Sterican sterile needle Regent, USA 
Sterile culture cell flask (75 cm2) BD Labware, USA 
Sterile filter flasks TPP, Switzerland 
Sterile surgical gloves  Regent, USA 
Whatman Filter paper Schleider & Schwell 
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8.2 Instruments 
Cell counter, Countess   Invitrogen 
Celloshaker variospeed Vialta, Italy 
Centrifuge, Biofuge, Heraeus, Fresco  DJB labcare Ltd, UK 
Electronic vibrofix Janke & Kunkel 
Kodak X-OMAT, 1000 processor KODAK 
Mettler Toledo Model, Delta range scale Mettler, Norway 
Microscope Olympus  Olympus Corps., Japan 
pH- meter PHM210 Meterlab, France 
Rotating device Labinco, Netherlands 
Titertek Multiskan PLUS Eflab, Finland 
 
8.3 Antibodies 
Antibody Dilution  
Primary antibody, mouse 
anti-human MMP-2 
1:1000 Biosciences Inc., San 
Diego 
Secondary antibody, 
sheep anti-mouse 
1: 3000 Amersham Biosciences, 
UK 
Monoclonal antibody 
CTD 110.6 
1: 5000 Covance, UK, MMS-
248R 
Secondary antibody,     
goat anti-mouse, IgM 
1: 5000 Sigma Aldrich Co, USA, 
Cat. NO: 8786 
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8.4 Chemicals 
Acrylamide  Sigma Aldrich, Germany 
Ammonium persulfate (APS) Bio-Rad, USA 
BC Assay protein quantification kit Uptima Interchim, France 
2-mercaptoethanol Sigma Aldrich, Norway 
Bovine Serum Albumin (BSA) Sigma Aldrich, Germany 
Bromphenol Blue Bio-Rad, USA 
Collagenase (0.2%) Sigma Aldrich, Germany 
Coomassie Brilliant Blue Sigma Aldrich, Germany 
Complete Mini EDTA-free Protease inhibitor, 
cocktail tablets 
Roche, Germany 
DON (6-diazo-5-oxo-norleucine)  Sigma Aldrich, Germany 
D (+) Glucose Sigma Aldrich, Germany 
ECL TM PLUS Western Blotting detection 
reagent 
Amersham, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich, Germany 
Epidermal growth factor (EGF) R&D systems, UK 
Foetal bovine serum (FBS) Sigma Aldrich, Germany 
Fibroblast growth factor (FGF) R&D systems, UK 
Fungisone GIBCO Invitrogen, UK 
Gelatin (Type A: From porcine skin, kat. G 
2500) 
Sigma Aldrich, Germany 
Glycerol Sigma Aldrich, Germany 
Glycine Sigma Aldrich, Germany 
Hepes Sigma Aldrich, Germany 
Hydrocortisone Sigma Aldrich, Germany 
Hydrochloric acid (HCl) Merck, Germany 
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MCDB-131 basis powder Sigma Aldrich, Germany 
Methanol Merck, Germany 
Precision Plus protein standards (all Blue) Bio-Rad, USA 
Precision Plus protein standards (Dual Colour) Bio-Rad, USA 
SDS (sodium dodecyl sulfat) Sigma-Aldrich, Norway 
TEMED Bio-Rad, USA 
Tris-Base  Calbiochem, USA 
Triton X-100 Merck, Germany 
Trypan blue solution Sigma Aldrich, Germany 
Tween  20 Sigma Aldrich, Germany 
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8.5 Solutions 
 
Table 8.5.0. Cord buffer 
Components Volume Final Concentration 
Streptomycin 0.5 g in 1 ml sterile MQ-H2O 50 mg/ l 
1X PBS (sterile) 1000 ml  
Stored at 4°C 
 
Table 8.5.1. 10x PBS pH 7.2-7.4 
Components Volume 
25 mM NaH2PO4 x H2O 3.9 g 
8 mM NaH2PO4 14.1 g 
NaCl 85.2 g 
MQ-H2O Up to 1000 ml 
The pH was adjusted to 7.2-7.4 by adding 1 M NaOH or 1 M HCl 
Table 8.5.2. 1x PBS  
 
 
Table 8.5.3. Collagenase (0.2%) 
Components Volume Final Concentration 
Collagenase 200 mg 0.2% 
1X PBS 100 ml  
 
Components Volume Final Concentration 
10x PBS 100 ml 1x 
MQ-H2O 900 ml  
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Table 8.5.4. Washing buffer  
Component Volume 
Triton X-100 2.5 ml 
MQ-H2O 97.5 ml 
 
 
Table 8.5.5. 10x Incubation buffer 
Component Grams 
10 mM Tris base 12.1 g 
40 mM Tris HCl 63.0 g 
200 mM NaCl2 117.0 g 
5 mM CaCl2 * H2O 7.4 g 
0.02% Brij 35 6.66 g 30% (w/v) Brij 35 Sigma 
Mixed in MQ-H2O giving a total volume of 1000 ml 
 
Table 8.5.6. Staining solution (2x) 
Component Grams/ ml 
Coomassie Brilliant Blue R-250 0.4g/ 1 tablet 
MQ-H2O 80 ml 
Methanol 120 ml 
The solution is ready for use after it has been mixed with 1 part acetic acid. 
Table 8.5.7. Destaining buffer 
Component Amount 
Methanol 120 ml 
Acetic acid, 
glacial 
40 ml 
MQ-H2O 240 ml 
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Table 8.5.8. Separation gel 
Components Volume 
1.5 M Tris pH 8.8 2.5 ml 
30 % Acrylamid solution 2.5 ml 
2% Gelatine 0.5 ml 
MQ-H2O 4.5 ml 
10% SDS 100 µl 
10% APS 50 µl 
TEMED 5 µl 
 
 
Table 8.5.9. Stacking gel 
Components Volume 
0.5 M Tris pH 6.8 1.3 ml 
30% acrylamid solution 0.7 ml 
MQ-H2O 3.25 ml 
10% SDS 50 µl 
10% APS 25 µl 
TEMED 5 µl 
 
 
Table 8.6.0. Running buffer pH 8.3 (10x) 
Components Volume 
Tris Base 29.0 g 
Glycin 144.0 g 
SDS 10.0 g 
MQ-H2O Up to 1000 ml 
 
66 
 
 
Table 8.6.1. Running buffer pH 8.3 (1x) 
Components Volume Final concentrations 
10x Running buffer 100 ml 1x 
MQ-H2O 900 ml  
 
 
 
Table 8.6.2. Loading buffer (4x) 
Components Volume Final concentration 
0.5 M Tris buffer pH 6.8 1.0 ml 0.05 M 
Glycerol 4.0 ml 40 % 
SDS 0.8g 0.08 % 
Bromphenol Blue 8.0 mg 8 % 
2-mercaptoethanol 1.0 ml 10 % 
MQ-H2O Up to 10 ml  
 
  
Table 8.6.3. Blotting buffer (10x)  
Components Final Concentration 
Trizma base 0.25 M 
Glycine 1.92 M 
 
Table 8.6.4. Blotting buffer (1x) 
Components Final Concentration 
Methanol 10-20 % 
10x blottingbuffer 1x 
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Table 8.6.5. Transfer buffer (10x) pH 7.4 
Components Volume 
Tris-HCl 39.4 g 
Glycine 143.0 g 
MQ-H2O Up to 1000 ml 
 
 
Table 8.6.6. Transfer buffer (1x) 
Components Volume Final Concentration 
Methanol  1000 ml 10 % 
10x Transfer buffer 100 ml 1x 
MQ-H2O 800 ml  
 
 
Table 8.6.7. TBS (10x) 
Components Final Concentration 
Trizma HCl 0.2 M 
NaCl 1.37 M 
Adjust pH to 7.6 with HCl 
 
Table 8.6.8. TBST (1x) 
Components Final Concentration 
10x TBST  1x 
Tween 20 0.1 % 
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Table 8.6.9. 1.0 M Glucose 
Components Volume Final Concentration 
D-(+)-Glucose 2.703 g 1.0 M 
MQ-H2O 15 ml  
The solution was sterile filtered 
 
Table 8.7.0. 10 M NaOH 
Components Volume Final Concentration 
NaOH 40 g 10 M 
MQ-H2O Up to 1000 ml  
 
Table 8.7.1. 1.0 M NaOH 
Components Volume Final Concentration 
NaOH 10 ml 1.0 M 
MQ-H2O 90 ml  
 
 
Table 8.7.2. 10 M HCl 
Components Volume Final Concentration 
HCl concentrated (12.1 M) 30 ml 10 M 
MQ-H2O Up to 100 ml  
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Table 8.7.3. 100 ml 1.0 M HCl 
Components Volume Final Concentration 
10 M HCl 10 ml 1.0 M 
MQ-H2O 90 ml  
 
 
Table 8.7.4. 0.5 M Tris pH 6.8 
Components Grams/ Volume 
Tris-Base 12 g 
MQ-H2O Up to 400 ml 
pH is adjusted to 6.8 with HCl 
 
Table 8.7.5. 1.5 M Tris pH 8.8 
Components Grams/ Volume 
Tris-Base 72.6 g 
MQ-H2O Up to 400 ml 
pH is adjusted to 8.8 with HCl 
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9 Appendix II 
Endothelial cells are from a different HUVEC donor, and indicate the same trend as in Figure 
4.1.  
 
Figure 9.1 Protein synthesis in response to glucose concentrations. HUVEC were cultured with 
different glucose concentrations (5 mM, 15 mM, 25 mM, and 40 mM) for 24 h in serum-free media. 
The results presented are from cell fractions originating from three separate wells. 
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Figure 9.2 Quantification of zymography bands from Figure 4.5A. Y-axis: Intensities (relative units). 
 
 
 
Figure 9.3 Quantification of zymography bands from Figure 4.6 
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“This sequence seems to contain a signal peptide!! 
Proteins with signal peptides are most probably secreted 
and are unlikely to contain an O-(beta)-GlcNAc site”. 
---------------------------------------------------------------------------
---- 
SeqName     Residue  O-GlcNAc  Potential  Thresh.  Thresh.   NetPhos  
YinOYang? 
                      result   (o-glcnac)   (1)      (2)    potential 
                                                          (Thresh=0.5) 
---------------------------------------------------------------------------
---- 
Sequence      199  T    +        0.4638    0.4387   0.5417             
Sequence      300  T*   +        0.4689    0.4581   0.5678     0.926       
* 
Sequence      307  T*   +        0.4429    0.4272   0.5262     0.804       
* 
Sequence      365  S*   +        0.4626    0.4370   0.5395     0.952       
* 
--------------------------------------------------------------------------- 
 
 
Figure 9.4 show four potential O-GlcNAcylated sites at MMP-2 protein (+). 
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YinOYang	  1.2	  output	  format 
 
Name:  HXA3_HUMAN       Length:  443 
(sequence) 
MQKATYYDSSAIYGGYPYQAANGFAYNANQQPYPASAALGADGEYHRPACSLQSPSSAGGHPKAHELSEACLRTL
SAPPS      80 
QPPSLGEPPLHPPPPQAAPPAPQPPQPAPQPPAPTPAAPPPPSSASPPQNASNNPTPANAAKSPLLNSPTVAKQI
FPWMK     160 
ESRQNTKQKTSSSSSGESCAGDKSPPGQASSKRARTAYTSAQLVELEKEFHFNRYLCRPRRVEMANLLNLTERQI
KIWFQ     240 
NRRMKYKKDQKGKGMLTSSGGQSPSRSPVPPGAGGYLNSMHSLVNSVPYEPQSPPPFSKPPQGTYGLPPASYPAS
LPSCA     320 
PPPPPQKRYTAAGAGAGGTPDYDPHAHGLQGNGSYGTPHIQGSPVFVGGSYVEPMSNSGPALFGLTHLPHAASGA
MDYGG     400 
AGPLGSGHHHGPGPGEPHPTYTDLTGHHPSQGRIQEAPKLTHL 
(annotation line, G=O-GlcNAc, Y=YinYang) 
...................................G...................GY..................
G...G      80 
..................................Y.......GG.Y.....G...G...................
.....     160 
.....Y...GYYY..........Y.....Y.....G..G....................................
.....     240 
................G.Y...Y.G...........................Y....G.....G......G...G
..G..     320 
........................................................................G..
.....     400 
........................................G.. 
 
---------------------------------------------------------------------------
---- 
SeqName     Residue  O-GlcNAc  Potential  Thresh.  Thresh.   NetPhos  
YinOYang? 
                      result   (o-glcnac)   (1)      (2)    potential 
                                                          (Thresh=0.5) 
---------------------------------------------------------------------------
---- 
HXA3_HUMAN     5  T    -        0.4047    0.4125   0.5064     <-- A 
negative site     
HXA3_HUMAN     9  S    -        0.4267    0.4631   0.5746             
HXA3_HUMAN    10  S    -        0.3548    0.4653   0.5776             
HXA3_HUMAN    36  S    ++       0.5781    0.4421   0.5463     <-- O-GlcNAc 
predicted (++)        
HXA3_HUMAN    51  S    -        0.4089    0.4299   0.5298             
HXA3_HUMAN    54  S    -        0.3183    0.3966   0.4849     0.783  <- 
Phos,No-GlcNAc 
HXA3_HUMAN    56  S    +        0.4483    0.3792   0.4615             
HXA3_HUMAN    57  S*   +        0.4357    0.3856   0.4702     0.967       * 
<- YinYang 
HXA3_HUMAN    68  S    -        0.2631    0.4479   0.5542             
HXA3_HUMAN    74  T    -        0.3126    0.4422   0.5464             
HXA3_HUMAN    76  S    ++       0.5023    0.3922   0.4791             
HXA3_HUMAN    80  S    +++      0.6007    0.3667   0.4447             
HXA3_HUMAN    84  S    -        0.2640    0.3769   0.4584     0.991        
HXA3_HUMAN   115  T*   +++      0.6261    0.3591   0.4344     0.770       * 
<- YinYang 
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. 
. 
. 
---------------------------------------------------------------------------
---- 
 
O-GlcNAc Result  
This can be one of 5 possibles:-  
   -  No O-GlcNAc predicted  
O-GlcNAc predicted: (different strengths)  
   +  Potential > Thresh-1  
  ++  Potential > Thresh-2          (Thresh-2 is a threshold based on more stringent surface 
measures)  
 +++  Potential > (Thresh-2 + 0.1)  
++++  Potential > (Thresh-2 + 0.1) AND Potential >= 0.75  
NetPhos  
These potentials are displayed if 'YinYang' output was selected and if the NetPhos potential  
crosses the NetPhos (fixed) threshold.  
Predictions are run in parallel from the NetPhos server.  
YinOYang  
Ser/Thr residues which are predicted to be O-GlcNAcylated as well as phosphorylated are  
marked by an asterisk (*) in both the residue and the YinOYang column. Such sites may be  
reversibly and dynamically modified by O-GlcNAc or Phosphate groups at different times  
in the cell.  
SignalP  
With all predictions, the SignalP server is run in parallel. If a sequence is predicted to contain  
a signal peptide, a warning is displayed. Such sequences are unlikely to be intracellular, and hence  
unlikely to be O-GlcNAcylated.  
Graph  
The figure illustrates O-GlcNAc and NetPhos predictions across the length of the sequence.  
The x-axis represents the sequence from N-terminal to C-terminal. Vertical impulses (green)  
are O-GlcNAc potentials. For predicted O-GlcNAcylated sites, these potentials would cross  
the threshold (blue wavy horizontal) line.  
Small red marks/circles on the green impulses indicate YinYang sites.  
 
 
 
